Multiple sclerosis (MS) is often characterized by an exacerbating/remitting course with chronic-progression of clinical disability. We have developed an animal model of experimental autoimmune encephalomyelitis (EAE) that shows a similar clinical profile. Immunization of (SWKxSJL)F1 mice with the immunodominant p139-151 determinant of myelin proteolipid protein (PLP) results in acute EAE, and recovery from the primary attack is followed by a relapsing- remitting pattern of disease with a subsequent chronic-progression of disability and demyelination reminiscent of MS. A number of studies have shown that acquired recognition of new self- determinants, a process commonly referred to as determinant spreading, accompanies chronic relapse and progression of EAE. We have recently shown that determinant spreading in EAE is an ordered physiologic process in which defined myelin self-determinants are recognized in a sequential predictable cascade. Moreover, we have found that tolerance induction after disease onset to spreading vs non-spreading determinants inhibits the subsequent chronic-progression of disease. Our results indicate that determinant spreading is not an epiphenomenon but is instead a pathogenic process mediating the progression of autoimmunity and providing a foundation for therapeutic intervention of on going disease. Our overall hypothesis is that autoimmune disease is a developmental evolving process in which predictable self recognition events accumulate in an orderly manner and cause chronic-progressive disease. In the current application, we will define the extent to which spreading is predictable by identifying features common to spreading cascades resulting from EAE induction by different means and with different determinants. In addition, we will define the therapeutic hierarchy of spreading determinants by tolerizing with peptides representing different stages of the spreading cascade. These experiments will identify determinants providing optimal protection from disease progression. Finally, we will determine the optimum conditions for interrupting the spreading cascade by immune deviation with determinant- specific Th2 T cells. The relevance of our work on the predictability of murine determinant spreading patterns lies in our complementary observations that the development of both EAE and MS share remarkably similar patterns of self-recognition plasticity. Our ultimate goal is to treat ongoing autoimmune demyelinating disease by predicting and therapeutically targeting the determinant spreading cascade. The studies outlined in this application will provide a rationale for the development of such therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS036054-04
Application #
6126328
Study Section
Special Emphasis Panel (ZRG1-NLS-3 (01))
Program Officer
Utz, Ursula
Project Start
1996-12-01
Project End
2001-11-30
Budget Start
1999-12-01
Budget End
2001-11-30
Support Year
4
Fiscal Year
2000
Total Cost
$156,729
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
017730458
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Altuntas, Cengiz Z; Johnson, Justin M; Tuohy, Vincent K (2006) Autoimmune targeted disruption of the pituitary-ovarian axis causes premature ovarian failure. J Immunol 177:1988-96
Jaini, Ritika; Hannaman, Drew; Johnson, Justin M et al. (2006) Gene-based intramuscular interferon-beta therapy for experimental autoimmune encephalomyelitis. Mol Ther 14:416-22
Edling, Andrea E; Tuohy, Vincent K (2005) Stem cell reconstitution of autoimmune T cell repertoires. J Neuroimmunol 169:126-36
Edling, Andrea E; Nanavati, Tania; Johnson, Justin M et al. (2004) Human and murine lymphocyte neurotrophin expression is confined to B cells. J Neurosci Res 77:709-17
Solares, C Arturo; Edling, Andrea E; Johnson, Justin M et al. (2004) Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides. J Clin Invest 113:1210-7
Solares, C Arturo; Hughes, Gordon B; Tuohy, Vincent K (2003) Autoimmune sensorineural hearing loss: an immunologic perspective. J Neuroimmunol 138:1-7
Lorenz, Robert R; Solares, C Arturo; Williams, Paul et al. (2002) Interferon-gamma production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss. J Neuroimmunol 130:173-8
Wujek, Jerome R; Bjartmar, Carl; Richer, Edward et al. (2002) Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 61:23-32
Jane-wit, Daniel; Yu, Min; Edling, Andrea E et al. (2002) A novel class II-binding motif selects peptides that mediate organ-specific autoimmune disease in SWXJ, SJL/J, and SWR/J mice. J Immunol 169:6507-14
Yin, L; Yu, M; Edling, A E et al. (2001) Pre-emptive targeting of the epitope spreading cascade with genetically modified regulatory T cells during autoimmune demyelinating disease. J Immunol 167:6105-12

Showing the most recent 10 out of 29 publications